Welcome to our dedicated page for Cellectar Biosciences NEW news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences NEW stock.
Cellectar Biosciences Inc. (symbol: CLRB) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative drugs aimed at treating cancer. The company's core focus is leveraging its proprietary Phospholipid Drug Conjugate (PDC) delivery platform, which is designed to target cancer cells specifically, thereby enhancing efficacy and reducing off-target effects.
Cellectar's PDC platform is founded on proprietary phospholipid ether analogs, small molecules known for their selective uptake and retention in various cancers. This technology underpins the company's product pipeline, which includes both therapeutic and diagnostic agents for oncology. The lead therapeutic candidate, CLR 131, utilizes the cytotoxic radioisotope iodine-131 as its payload. CLR 131 has received orphan drug designation from the US FDA and is currently being evaluated in a Phase 1 clinical study for relapsed or refractory multiple myeloma and a Phase 2 clinical study for a range of B-cell malignancies.
In addition to CLR 131, Cellectar is working on developing proprietary PDCs for targeted chemotherapeutic delivery, with several candidates in preclinical stages. The company actively collaborates with research and development partners to expand its PDC platform's applications.
Financially, Cellectar maintains a robust pipeline and continues to secure funding for its clinical and preclinical programs. The company’s innovative approach and partnerships highlight its significant role in the biopharmaceutical landscape.
For more detailed and latest updates, please visit Cellectar’s official website or follow their social media channels.
Cellectar Biosciences (NASDAQ: CLRB) has formed a collaboration with South Korea-based LegoChemBio for developing first-in-class phospholipid drug conjugates (PDCs). This partnership aims to leverage both companies' technologies to create new therapies targeting solid tumors with unmet medical needs. The agreement allows for joint development of three novel PDC candidates and offers options for global commercialization rights. Financial terms remain undisclosed. Both companies are optimistic about enriching their oncology pipelines and advancing cancer treatment.
Cellectar Biosciences, focused on cancer treatment, announced that President and CEO James Caruso will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 3:00 pm. The presentation will detail the company's drug development initiatives, including the CLR 131 treatment for Waldenstrom’s macroglobulinemia. A replay will be available on their website after the event. Cellectar utilizes its proprietary Phospholipid Drug Conjugate™ platform to create targeted cancer therapies, aiming for improved efficacy and safety.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced the election of Dr. Asher Alban Chanan-Khan to its board of directors as an independent director. Dr. Chanan-Khan brings extensive experience in oncology, notably in hematologic cancers, and will play a critical role in advancing the company's cancer-targeting assets, including CLR 131. The company continues to focus on developing drugs that leverage its Phospholipid Drug Conjugate™ platform, which aims for improved efficacy in cancer treatment.
Cellectar Biosciences, Inc. (CLRB) presented promising results at the ASCO Annual meeting regarding CLR 131, a treatment for relapsed/refractory B-cell hematologic cancers. The Phase 2 CLOVER-1 study revealed a 100% overall response rate in six patients with Waldenstrom's macroglobulinemia, including an 83.3% major response rate and a 16.7% complete response rate. Notably, mean treatment-free remission is 1.1 years, with progression-free survival not yet reached after 18 months for high-risk patients. The ongoing trial aims to enroll 50 WM patients and explore further efficacy and safety outcomes.
Cellectar Biosciences (NASDAQ: CLRB) has announced a virtual poster presentation at the ASCO Annual Meeting from June 4-8, 2021, detailing findings from its Phase 2a study of CLR 131 in Waldenstrom’s macroglobulinemia (WM). The presentation will highlight results from six patients. Management will host a KOL call with Dr. Sikandar Ailawadhi, the lead investigator, on June 4 at 10:00 am. CLR 131 targets cancer cells using the company’s Phospholipid Drug Conjugate (PDC) delivery platform and is part of a pivotal trial aimed at understanding treatment responses in WM patients.
On May 14, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced its participation in the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021. The company will be available for one-on-one meetings and will host an on-demand presentation for registered participants. Cellectar is focused on developing cancer-targeted therapies using its proprietary Phospholipid Drug Conjugate™ delivery platform. The company’s product pipeline includes CLR 131 and other preclinical PDC programs aimed at enhancing treatment efficacy and safety for cancer patients.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced a pivotal study initiation of CLR 131 for Waldenstrom’s macroglobulinemia, titled CLOVER-WaM, aiming to enroll 50 patients. The study is aligned with FDA feedback and focuses on a major response rate.
The company received European Orphan Drug Designation for CLR 131, granting 10 years of market exclusivity. As of March 31, 2021, Cellectar holds approximately $54 million in cash, supporting operations into Q3 2023. Q1 net loss increased to $6.4 million, or $0.13 per share, compared to a loss of $4.0 million, or $0.42 per share, last year.
Cellectar Biosciences (NASDAQ: CLRB) announced the grant of a new patent titled "Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles" by patent authorities in Eurasia, Australia, and Mexico. This patent provides protection for their phospholipid-ether (PLE) analogs used in combination with various small molecule chemotherapies. CEO James Caruso highlighted the patent's role in enhancing their phospholipid drug conjugate (PDC) platform, aimed at improving drug efficacy and safety in cancer treatment. Their lead candidate, CLR 131, is in pivotal clinical studies for hematologic cancers.
On March 11, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced that its CEO, James Caruso, will present at two upcoming conferences. The Oppenheimer 31st Annual Healthcare Conference is scheduled for March 16, 2021, at 8:00 am ET, with opportunities for 1x1 meetings. The Maxim Group 2021 Emerging Growth Virtual Conference takes place from March 17-19, 2021. Cellectar focuses on cancer treatment drug development, particularly through its Phospholipid Drug Conjugate™ platform.
Cellectar Biosciences (NASDAQ: CLRB) announced on March 9, 2021, that the Japan Patent Office granted patent number 6832861 for its phospholipid-ether (PLE) analogs, enhancing its intellectual property portfolio. This patent secures composition of matter and use for these analogs in combination with various small molecule chemotherapeutics, bolstering their Phospholipid Drug Conjugates™ (PDCs™) franchise. Lead candidate CLR 131 continues to progress in clinical studies for both adult and pediatric cancer indications.
FAQ
What is the current stock price of Cellectar Biosciences NEW (CLRB)?
What is the market cap of Cellectar Biosciences NEW (CLRB)?
What is Cellectar Biosciences' primary focus?
What is the lead therapeutic candidate of Cellectar Biosciences?
What are the current clinical trials for CLR 131?
Has CLR 131 received any designations from the FDA?
What is the proprietary technology behind Cellectar's PDC platform?
Is Cellectar Biosciences involved in any partnerships?
What other products are under development at Cellectar?
Where can I find more information about Cellectar Biosciences?
How does Cellectar's PDC platform improve cancer treatment?
What makes Cellectar Biosciences significant in the biopharmaceutical field?
